Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance.
- NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_assertion description "[In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance.
- NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_assertion evidence source_evidence_literature NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance.
- NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_assertion SIO_000772 23671644 NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance.
- NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_assertion wasDerivedFrom befree-20140225 NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance.
- NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_assertion wasGeneratedBy ECO_0000203 NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance.
- befree-20140225 importedOn "2014-02-25" NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance.